Category: Cancer

Oncotarget Stays True to Its Mission of Enhancing Faster Sharing Of Exceptional Scientific Discoveries

There are four main leading factors why researchers choose one journal publication over the other: reputation of the journal, relevance of the publication content, quality and transparency of the peer review process, and the journal’s readership influence and impact factor.In the Oncology and cancer research, one of the top publications that combine all of the highlighted factors is Oncotarget. To begin with, the journal is highly ranked as one of the top open-access journals globally—with an average impact factor of 5.0 for the past 5 years. Its editorial board is also comprised of reputed scholars and researchers, most of whom boasts of numerous accolades in the medical research world including the Breakthrough Prize and the Laser Prize.Oncotarget’s publication process is also straightforward and impartial: researchers and scholars who want their studies published can easily find the necessary information and resources that they need on Oncotarget’s website.While the primary focus of the publication is oncology, Oncotarget also publishes research papers in the fields of pathology, immunology, age-related diseases, and endocrinology. The Journal’s editors decided to publish papers in other fields as well to allow the researchers in these fields to also leverage on the success behind the publication.

Making scientific research widely available

Unlike other journals which require subscription, Oncotarget is free to access. In fact, each of their weekly issues can be printed on special demand.The publication’s mission is to make scientific research easily available by enhancing faster sharing of exceptional discoveries. The publication also aims at maximizing the impact of scientific research through capitalizing on insightful review. This subsidiary of Impact Journal is also focused at eliminating the border between different specialties and fostering application of clinical and basic science in fighting diseases.

This move has resulted into positive cross-border collaboration between researchers, something that wasn’t initially possible.One of the recent researches that Oncotarget published is an article on Salvage Therapy for Relapsed Testicular Cancer. The article has brought a lot of hope to patients diagnosed with testicular cancer and who were uncertain of the treatment options available. The article highlights some of the causes of this type of cancer as well as how it can be treated and prevented.

Octotarget Proposes Oncology as the Right Cancer Treatment

Octotarget is a medical journal published on a weekly basis addressing issues on the field of oncology. The journal is published by impact journals and is both open to all for free and is peer reviewed. The term peer reviewed indicates that the contents contained in the journal are subjected to scrutiny by scholars and practitioners in the field of oncology and proven to be factually and pragmatically accurate. The chief editors for Octotarget are Mikhail Blagosklonny and Andrei V. Gudkov of Roswell Park Cancer Institute.

Oncology is an area of the medical field that concerns itself with the prevention treatment of cancer after diagnosis. This field brings together the three components which have been identified as the most important in enhancing survival for cancer patients. These are prevention, early diagnosis, and proper treatment. This would involve such steps as avoiding such potent causes for cancer such as tobacco and alcohol, taking a regular screening for common cancers and pursuing a multimodal treatment method once one has been diagnosed with the disease.

Octotarget’s editor in chief Mikhail Blagosklonny believes passionately that the cancer treatment drug rapamycin could be quite useful in enhancing life extension as well as it has been effective in cancer treatment. Mr. Mikhail Blagosklonny studies cancer and aging and previously served as an oncology professor at the Roswell Park Cancer Center. He earned a masters’ degree in internal medicine and a Ph.D. in experimental medicine cardiology, both from the First Pavlov State Medical University of St. Peterburg. He served as an associate professor at the New York Medical College and later as a senior scientist at Ordway Research Institute at Albany in New York. He would then be appointed to the position of Oncology Professor at the Roswell Park Cancer Institute in 2009, just before the founding of the Octotarget Journal in 2010 in the following: click here.

Octotarget mainly concerns itself with propelling oncological ideas which posit a natural based approach to cancer prevention and treatment. Mr. Blagosklonny believes that the right treatment of cancer would also serve as the right anti-aging treatment, and this message is reflected in the journal.